Cargando…

Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014

Antiviral treatment of immunocompromised patients with prolonged influenza virus infection can lead to multidrug resistance. This study reveals the selection of antiviral resistance mutations in influenza A(H1N1)pdm09 virus in an immunocompromised patient during a 6-month period. The patient was tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Trebbien, Ramona, Pedersen, Svend Stenvang, Vorborg, Kristine, Franck, Kristina Træholt, Fischer, Thea Kølsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Centre for Disease Prevention and Control (ECDC) 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322288/
https://www.ncbi.nlm.nih.gov/pubmed/28128091
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.3.30445
_version_ 1782509816921456640
author Trebbien, Ramona
Pedersen, Svend Stenvang
Vorborg, Kristine
Franck, Kristina Træholt
Fischer, Thea Kølsen
author_facet Trebbien, Ramona
Pedersen, Svend Stenvang
Vorborg, Kristine
Franck, Kristina Træholt
Fischer, Thea Kølsen
author_sort Trebbien, Ramona
collection PubMed
description Antiviral treatment of immunocompromised patients with prolonged influenza virus infection can lead to multidrug resistance. This study reveals the selection of antiviral resistance mutations in influenza A(H1N1)pdm09 virus in an immunocompromised patient during a 6-month period. The patient was treated with two courses of oseltamivir (5 days and 2 months, respectively), with the first course starting at symptom onset, and subsequently zanamivir (2 months and 10 days, respectively). Respiratory samples were investigated by Sanger and next generation sequencing (NGS) and, for NGS data, low-frequency-variant-detection analysis was performed. Neuraminidase-inhibition tests were conducted for samples isolated in Madin-Darby canine kidney cells. In a sample collected 15 days after the end of the first treatment with oseltamivir (Day 20 post-symptom onset), oseltamivir resistance was detected (mutation H275Y with 60.3% frequency by NGS). Day 149 when the patient had almost completed the second zanamivir treatment, mixes of the following resistance mutations were detected; H275Y(65.1%), I223R(9.2%), and E119G(89.6%), accompanied by additional mutations, showing a more complex viral population in the long-term treated patient. Two samples obtained on Day 151 from bronchoalveolar lavage (BAL) and nasopharyngeal swab, respectively, showed different mutation profiles, with a higher frequency of antiviral resistance mutations in BAL. The results emphasise the importance of timely antiviral resistance testing both for treatment of individual patients as well as for preventive measures to control the development and transmission of antiviral resistant viruses.
format Online
Article
Text
id pubmed-5322288
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher European Centre for Disease Prevention and Control (ECDC)
record_format MEDLINE/PubMed
spelling pubmed-53222882017-03-03 Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014 Trebbien, Ramona Pedersen, Svend Stenvang Vorborg, Kristine Franck, Kristina Træholt Fischer, Thea Kølsen Euro Surveill Research Article Antiviral treatment of immunocompromised patients with prolonged influenza virus infection can lead to multidrug resistance. This study reveals the selection of antiviral resistance mutations in influenza A(H1N1)pdm09 virus in an immunocompromised patient during a 6-month period. The patient was treated with two courses of oseltamivir (5 days and 2 months, respectively), with the first course starting at symptom onset, and subsequently zanamivir (2 months and 10 days, respectively). Respiratory samples were investigated by Sanger and next generation sequencing (NGS) and, for NGS data, low-frequency-variant-detection analysis was performed. Neuraminidase-inhibition tests were conducted for samples isolated in Madin-Darby canine kidney cells. In a sample collected 15 days after the end of the first treatment with oseltamivir (Day 20 post-symptom onset), oseltamivir resistance was detected (mutation H275Y with 60.3% frequency by NGS). Day 149 when the patient had almost completed the second zanamivir treatment, mixes of the following resistance mutations were detected; H275Y(65.1%), I223R(9.2%), and E119G(89.6%), accompanied by additional mutations, showing a more complex viral population in the long-term treated patient. Two samples obtained on Day 151 from bronchoalveolar lavage (BAL) and nasopharyngeal swab, respectively, showed different mutation profiles, with a higher frequency of antiviral resistance mutations in BAL. The results emphasise the importance of timely antiviral resistance testing both for treatment of individual patients as well as for preventive measures to control the development and transmission of antiviral resistant viruses. European Centre for Disease Prevention and Control (ECDC) 2017-01-19 /pmc/articles/PMC5322288/ /pubmed/28128091 http://dx.doi.org/10.2807/1560-7917.ES.2017.22.3.30445 Text en This article is copyright of The Authors, 2017. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.
spellingShingle Research Article
Trebbien, Ramona
Pedersen, Svend Stenvang
Vorborg, Kristine
Franck, Kristina Træholt
Fischer, Thea Kølsen
Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
title Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
title_full Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
title_fullStr Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
title_full_unstemmed Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
title_short Development of oseltamivir and zanamivir resistance in influenza A(H1N1)pdm09 virus, Denmark, 2014
title_sort development of oseltamivir and zanamivir resistance in influenza a(h1n1)pdm09 virus, denmark, 2014
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322288/
https://www.ncbi.nlm.nih.gov/pubmed/28128091
http://dx.doi.org/10.2807/1560-7917.ES.2017.22.3.30445
work_keys_str_mv AT trebbienramona developmentofoseltamivirandzanamivirresistanceininfluenzaah1n1pdm09virusdenmark2014
AT pedersensvendstenvang developmentofoseltamivirandzanamivirresistanceininfluenzaah1n1pdm09virusdenmark2014
AT vorborgkristine developmentofoseltamivirandzanamivirresistanceininfluenzaah1n1pdm09virusdenmark2014
AT franckkristinatræholt developmentofoseltamivirandzanamivirresistanceininfluenzaah1n1pdm09virusdenmark2014
AT fischertheakølsen developmentofoseltamivirandzanamivirresistanceininfluenzaah1n1pdm09virusdenmark2014